Stock Detail
EPICEPT CORPORATION
Diagnostic Substances
EPCT @ Yahoo Finance | EPCT Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.65 | $0.67 | $-0.01 | -1.55% | 0.00 | $0.66 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.65 | $0.64 | 344,528 | 39.49M | 174,609 | -2.03 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.68 | 0.66 | 0.65 | 0.63 | 0.62 |
Stock Profile
EpiCept Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for the treatment of cancer and pain. It offers Ceplene, which is used for the treatment of acute myeloid leukemia. The company also provides EpiCept NP-1, a late-stage pain product candidate, for relief from the pain of peripheral neuropathies; LidoPAIN SP, a sterile prescription analgesic patch designed to provide sustained topical delivery of lidocaine to a post-surgical or post-traumatic sutured wound; and LidoPAIN BP, a prescription analgesic non-sterile patch designed to provide sustained topical delivery of lidocaine for the treatment of acute or recurrent lower back pain; and Azixa, a Phase II clinical trial product, for the treatment of cancer that has metastasized to the brain. In addition, it offers EpiCept MP/DP, an earlier-stage product candidate, which is a topical spray gel matrix, containing morphine and lidocaine for oral mucositis; LidoPAIN TV for the treatment of tinnitus; and LidoPAIN HM for the treatment of headache. It also develops EPC2407, a Phase I clinical trial product, for the treatment of patients with advanced solid tumors and lymphomas; EP2167, a pre-clinical stage product, a compound that induce apoptosis in cancer cells in multiple cell lines, including prostate, breast, colorectal, non-small cell lung and small cell lung cancers, and leukemia; and EP128504, an inducer of apoptosis for treatment of cancer in breast and colorectal cancer cells. The company has strategic alliances with DURECT Corporation; Endo Pharmaceuticals, Inc.; and Myriad Genetics, Inc. EpiCept was founded in 1993 and is based in Tarrytown, New York.